MedReleaf has introduced a new medicinal cannabis brand to the Australian market, developed alongside Canadian company Aurora Cannabis.
The brand, called CraftPlant, features three products available for doctors to prescribe — Greendae, Navana and HiVolt — all of which are THC-dominant and contain high concentrations of terpenes.
The products are manufactured under EU-GMP certified conditions and will come in 10g containers.
CEO Russell Harding said: "These new products are the result of dedicated hard work by the teams in both Canada and Australia, providing the most unique cannabis cultivars available in the Australian medical market.
"With CraftPlant, doctors now have 27 MedReleaf products available… providing a wide range of possible solutions for patients unable to obtain relief from their prior medications or treatment, and produced under the strictest guidelines."
Aurora Cannabis CEO Miguel Martin added: "As we build on our strategic international growth plans, Australia has proven to be a very promising and sustainable cannabis market that we are committed to."
Aurora holds a 10% stake in MedReleaf Australia.
